Browse result page of CancerPDF Database

Please click on CancerPDF_ID for detailed information about peptide.

CancerPDF_IDPeptide seqProtein NameFluidMass/ZProfiling TechniqueCancer Type Expression RegulationPUBMED ID
CancerPDF_ID141 LKLDGKFAlpha-2-HS-glycoproteinPlasmaNAMALDI-TOFNormal NA 17269714
CancerPDF_ID142 ISRAQLVPLPPSTAlpha-2-HS-glycoproteinPlasmaNAMALDI-TOFNormal NA 17269714
CancerPDF_ID143 ISRAQLVPLPPSTYAlpha-2-HS-glycoproteinPlasmaNAMALDI-TOFNormal NA 17269714
CancerPDF_ID144 EEISRAQLVPLPPSTAlpha-2-HS-glycoproteinPlasmaNAMALDI-TOFNormal NA 17269714
CancerPDF_ID145 VSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinPlasmaNAMALDI-TOFNormal NA 17269714
CancerPDF_ID146 EEISRAQLVPLPPSTYAlpha-2-HS-glycoproteinPlasmaNAMALDI-TOFNormal NA 17269714
CancerPDF_ID1659 PSGEVSHPRAlpha-2-HS-glycoproteinSerum964.47264LC-MSColorectal cancer NA 21136997
CancerPDF_ID1660 SPSGEVSHPRAlpha-2-HS-glycoproteinSerum1051.50467LC-MSColorectal cancer NA 21136997
CancerPDF_ID1661 GSPSGEVSHPRAlpha-2-HS-glycoproteinSerum1108.52613LC-MSColorectal cancer NA 21136997
CancerPDF_ID1662 PSGEVSHPRKTAlpha-2-HS-glycoproteinSerum1193.61528LC-MSColorectal cancer NA 21136997
CancerPDF_ID1663 VVSLGSPSGEVSHPRAlpha-2-HS-glycoproteinSerum1506.77906LC-MSColorectal cancer NA 21136997
CancerPDF_ID1664 LGSPSGEVSHPRAlpha-2-HS-glycoproteinSerum1221.6102LC-MSColorectal cancer NA 21136997
CancerPDF_ID1665 SLGSPSGEVSHPRAlpha-2-HS-glycoproteinSerum1308.64223LC-MSColorectal cancer NA 21136997
CancerPDF_ID1666 GSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum1337.66878LC-MSColorectal cancer NA 21136997
CancerPDF_ID1667 VVSLGSPSGEVSHPAlpha-2-HS-glycoproteinSerum1350.67794LC-MSColorectal cancer NA 21136997
CancerPDF_ID1668 LGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum1450.75284LC-MSColorectal cancer NA 21136997
CancerPDF_ID1669 SLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum1537.78487LC-MSColorectal cancer NA 21136997
CancerPDF_ID1670 FMGVVSLGSPSGEVSHPRAlpha-2-HS-glycoproteinSerum1841.90942LC-MSColorectal cancer NA 21136997
CancerPDF_ID1671 HTFMGVVSLGSPSGEVSHPAlpha-2-HS-glycoproteinSerum1939.90981LC-MSColorectal cancer NA 21136997
CancerPDF_ID1672 HTFMGVVSLGSPSGEVSHPRAlpha-2-HS-glycoproteinSerum2080.01601LC-MSColorectal cancer NA 21136997
CancerPDF_ID1673 HTFMGVVSLGSPSGEVSHPRAlpha-2-HS-glycoproteinSerum2096.01092LC-MSColorectal cancer NA 21136997
CancerPDF_ID1674 HTFMGVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum2309.15865LC-MSColorectal cancer NA 21136997
CancerPDF_ID1675 HTFMGVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum2325.15356LC-MSColorectal cancer NA 21136997
CancerPDF_ID1676 AHYDLRHTFMGVVSLGSPSGEVSHPRAlpha-2-HS-glycoproteinSerum2835.38748LC-MSColorectal cancer NA 21136997
CancerPDF_ID1677 VSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum1636.85328LC-MSColorectal cancer NA 21136997
CancerPDF_ID1678 FMGVVSLGSPSGEVSHPAlpha-2-HS-glycoproteinSerum1685.80831LC-MSColorectal cancer NA 21136997
CancerPDF_ID1679 HTFMGVVSLGSPSGEVSHPAlpha-2-HS-glycoproteinSerum1923.9149LC-MSColorectal cancer NA 21136997
CancerPDF_ID1680 SPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum1280.64731LC-MSColorectal cancer NA 21136997
CancerPDF_ID1681 AHYDLRHTFMGVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum3064.53012LC-MSColorectal cancer NA 21136997
CancerPDF_ID1682 VVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum1735.9217LC-MSColorectal cancer NA 21136997
CancerPDF_ID1683 HTFMGVVSLGSPSGAlpha-2-HS-glycoproteinSerum1374.66019LC-MSColorectal cancer NA 21136997
CancerPDF_ID1684 FMGVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum2071.05206LC-MSColorectal cancer NA 21136997
CancerPDF_ID1685 HTFMGVVSLGSPSGEVSAlpha-2-HS-glycoproteinSerum1689.80322LC-MSColorectal cancer NA 21136997
CancerPDF_ID1686 VSLGSPSGEVSHPRAlpha-2-HS-glycoproteinSerum1407.71064LC-MSColorectal cancer NA 21136997
CancerPDF_ID3208 HTLNQIDEVKAlpha-2-HS-glycoproteinPlasma1195.6197LC-MSNormal NA 21136997
CancerPDF_ID3209 HTFMGVVSLGSPSGEVSHPAlpha-2-HS-glycoproteinPlasma1923.9149LC-MSNormal NA 21136997
CancerPDF_ID3210 HTFMGVVSLGSPSGEVSHPRAlpha-2-HS-glycoproteinPlasma2080.016LC-MSNormal NA 21136997
CancerPDF_ID3211 HTFMGVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinPlasma2309.1586LC-MSNormal NA 21136997
CancerPDF_ID3212 HTFMGVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinPlasma2325.1536LC-MSNormal NA 21136997
CancerPDF_ID3213 AHYDLRHTFMGVVSLGSPSGEVSHPRAlpha-2-HS-glycoproteinPlasma2835.3875LC-MSNormal NA 21136997
CancerPDF_ID3214 AHYDLRHTFMGVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinPlasma3064.5301LC-MSNormal NA 21136997
CancerPDF_ID3595 SLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinUrineNA"CE-MS, Micro-TOF-MS"Bladder cancer Differentially expressed between recurrence of UBC vs recurrence control 27026199
CancerPDF_ID4314 APHGPGLIYRQPNCDDAlpha-2-HS-glycoproteinUrineNANano-LC-MSOvarian cancer Uniquely present in case of urine of ovarian cancer patients 24982608
CancerPDF_ID5664 KVWPQQPSGELFAlpha-2-HS-glycoproteinUrineNANano-LC-MSOvarian cancer Uniquely present in case of urine of ovarian cancer patients 24982608
CancerPDF_ID5665 KVWPQQPSGELFEIAlpha-2-HS-glycoproteinUrineNANano-LC-MSOvarian cancer Uniquely present in case of urine of ovarian cancer patients 24982608
CancerPDF_ID5666 KVWPQQPSGELFEIEIDTLAlpha-2-HS-glycoproteinUrineNANano-LC-MSOvarian cancer Uniquely present in case of urine of ovarian cancer patients 24982608
CancerPDF_ID5667 KVWPQQPSGELFEIEIDTLETAlpha-2-HS-glycoproteinUrineNANano-LC-MSOvarian cancer Uniquely present in case of urine of ovarian cancer patients 24982608
CancerPDF_ID7061 SRAQLVPLPPSTYVAlpha-2-HS-glycoproteinUrineNANano-LC-MSOvarian cancer Uniquely present in case of urine of ovarian cancer patients 24982608
CancerPDF_ID7062 SRAQLVPLPPSTYVEFTVAlpha-2-HS-glycoproteinUrineNANano-LC-MSOvarian cancer Uniquely present in case of urine of ovarian cancer patients 24982608
CancerPDF_ID8093 VVSLGSPSGEVSHPAlpha-2-HS-glycoproteinUrineNANano-LC-MSOvarian cancer Uniquely present in case of urine of ovarian cancer patients 24982608
CancerPDF_ID8094 VVSLGSPSGEVSHPRAlpha-2-HS-glycoproteinUrineNANano-LC-MSOvarian cancer Uniquely present in case of urine of ovarian cancer patients 24982608
CancerPDF_ID8095 VVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinUrineNANano-LC-MSOvarian cancer Uniquely present in case of urine of ovarian cancer patients 24982608
CancerPDF_ID8669 VVSLGSPSGEVSHPRAlpha-2-HS-glycoproteinSerum1505MALDI-TOFColorectal cancer Diffrentially expressed 24618180
CancerPDF_ID8671 AAAGPVVPPCPGRAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8688 AGPVVPPCPGRIRAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8705 APGLPPAGSPPDSAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8706 APGLPPAGSPPDSHAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8707 APGLPPAGSPPDSHVLAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8708 APGLPPAGSPPDSHVLLAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8709 APGLPPAGSPPDSHVLLAAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8710 APHGPGLIYRQPNCDDPETEEAAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8892 GPGLIYRQPNCDDPETEEAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8902 GPVVPPCPGRIRAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8926 GVVSLGSPSGEVSHPAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8934 HGPGLIYRQPNCDDPETEEAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8995 IYRQPNCDDPETEEAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID8996 IYRQPNCDDPETEEAAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9050 LPPAGSPPDSHVLAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9051 LPPAGSPPDSHVLLAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9052 LPPAGSPPDSHVLLAAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9259 SPPDSHVLLAAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9283 TCHVLDPTPVARCAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9349 TVVQPSVGAAAAlpha-2-HS-glycoproteinAscites fluidNALTQ-Orbitrap XLOvarian cancer Uniquely expressed in ovarian cancer patient 24694173
CancerPDF_ID9646 TVVQPSVGAAAAlpha-2-HS-glycoproteinSerum500.27LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9647 SGEVSHPRKTAlpha-2-HS-glycoproteinSerum549.28LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9648 HTFMGVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum578.3LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9649 HTFMGVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum582.3LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9650 SPSGEVSHPRAlpha-2-HS-glycoproteinSerum526.76LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9651 TVVQPSVGAAAGAlpha-2-HS-glycoproteinSerum528.78LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID9652 GVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum598.65LC-MSLung adenocarcinoma "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" 21533267
CancerPDF_ID10109 VSLGSPSGEVSHPRAlpha-2-HS-glycoproteinUrine1408.7185MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID10187 ISRAQLVPLPPSTYAlpha-2-HS-glycoproteinUrine1541.8717MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID10238 VSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinUrine1637.8584MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID10285 VVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinUrine1736.9297MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID10310 ISRAQLVPLPPSTYVEAlpha-2-HS-glycoproteinUrine1769.9784MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID10318 GVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinUrine1793.9484MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID10320 LAAPPGHQLHRAHYDLAlpha-2-HS-glycoproteinUrine1795.974MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID10417 YINQNLPWGYKHTLNQAlpha-2-HS-glycoproteinUrine1988.9979MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID10637 VAIDYINQNLPWGYKHTLNQIDEAlpha-2-HS-glycoproteinUrine2744.3252MALDI-TOFMuscle-invasive bladder cancer Differentially expressed between cancer vs normal samples 21805675
CancerPDF_ID11053 MGVVSLGSPSGEVSHPRKTAlpha2-HS glycoproteinSerum1925.5MALDI-TOFEsophageal squamous cell carcinoma (ESCC) Downregulated in patients vs normal with mean intensity in cancer 149.51 and mean intensity in normal as 590.32 26993605
CancerPDF_ID12206 SLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum1537.7849LC-MSMelanoma "Present in 4 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." 26992070
CancerPDF_ID12240 SPSGEVSHPRAlpha-2-HS-glycoproteinSerum1051.5047LC-MSMelanoma "Present in 2 cancer samples out of 8 cancer samples. ,Present in 0 healthy samples out of 4 healthy samples." 26992070
CancerPDF_ID12241 SPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum1280.6473LC-MSMelanoma "Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." 26992070
CancerPDF_ID12694 HTFMGVVSLGSPSGEVSHPRKTAlpha-2-HS-glycoproteinSerum2326.204MALDI-TOFBreast cancer "Upregulated with the fold change of 0.58 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.25, Upregulated in BC vs healthy with 1.217 fold change" 27058005